Franco-American drugmaker Rhone-Poulenc Rorer has promoted ThierrySoursac, currently president of its RPR Gencell subsidiary (a position he will retain), to senior vice president, worldwide research, reporting to R-PR's president of R&D and group executive vice president, Manfred Karobath. He replaces John Taylor who, until his retirement in May 1998, will be a scientific adviser for chemistry. The aim of the appointment of Dr Soursac is to boost research output.
In addition, Francois Meyer has been moved up to the position of vice president, worldwide research, and Gary Shearman to senior vice president, pharmaceutical drug development.
Meantime, R-PR has created a new management structure in Japan to become more responsive to its customers and accelerate growth in the region.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze